Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Topography-dependent Prognostic Value of CDK5 in Cetuximab-Treated, RAS/BRAF-wild-type Metastatic Colorectal Cancer:

Qinghua Wang1,2, Hongjuan Zheng2, Zhijian Zheng2

  • 1Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Cancer Control : Journal of the Moffitt Cancer Center
|May 15, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis.

Cancer biology & therapy·2024
Same author

Higher Levels of Tumour-Infiltrating Lymphocytes (TILs) are Associated with a Better Prognosis, While CDK5 Plays a Different Role Between Nonmetastatic and Metastatic Colonic Carcinoma.

Cancer control : journal of the Moffitt Cancer Center·2023
Same author

The value of PET/CT for the diagnosis and evaluation of immunotherapy in occult primary renal cell carcinoma: a case report.

The Journal of international medical research·2023
Same author

The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups.

PloS one·2023
Same author

A Prediction Model for Chemotherapy-Induced Thrombocytopenia Based on Real-World Data and a Close Relationship Between AST/ALT Ratio and Platelet Count in Patients with Solid Tumors.

International journal of general medicine·2022
Same author

Metabolomics studies on cachexia in patients with cancer: a scoping review protocol.

BMJ open·2022

Elevated cyclin-dependent kinase 5 (CDK5) expression predicts shorter survival in metastatic colorectal cancer patients treated with cetuximab. This prognostic value is lost when cancer spreads to the liver.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Metastatic colorectal cancer (mCRC) patients with dual wild-type RAS/BRAF mutations often receive cetuximab treatment.
  • Predictive biomarkers are crucial for optimizing treatment strategies in refractory mCRC.
  • Cyclin-dependent kinase 5 (CDK5) has emerged as a potential factor influencing cancer progression.

Purpose of the Study:

  • To investigate the prognostic significance of cyclin-dependent kinase 5 (CDK5) expression in patients with cetuximab-treated, chemotherapy-refractory, dual wild-type RAS/BRAF metastatic colorectal adenocarcinoma.
  • To determine if CDK5 expression levels correlate with progression-free survival (PFS) and cancer-specific survival (CSS).

Main Methods:

  • Retrospective analysis of 129 mCRC patient samples using immunohistochemistry (IHC) to assess CDK5 expression.
Keywords:
RAS wild-typecolorectal adenocarcinomacyclin-dependent kinase 5 (CDK5)hepatic metastasisprognosis

Related Experiment Videos

Last Updated: May 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

  • Statistical analysis including Pearson's chi-squared test, Kaplan-Meier curves, log-rank tests, and Cox proportional-hazards models.
  • Correlation of CDK5 expression levels (low-to-intermediate vs. high) with clinicopathological variables and survival outcomes.

    • Main Results:

    • Elevated CDK5 immunoreactivity was associated with significantly inferior PFS (7.0 vs. 9.0 months, P=0.049) and CSS (27.8 vs. 38.5 months, P=0.048).
    • Low-to-intermediate CDK5 expression was an independent predictor of improved PFS (HR 0.544) and CSS (HR 0.502).
    • CDK5 overexpression significantly worsened PFS in patients with extra-hepatic metastases (P=0.012) but not in those with liver metastases (P=0.800).

    Conclusions:

    • Elevated CDK5 expression is a robust independent predictor of shorter PFS and CSS in this mCRC cohort.
    • The prognostic impact of CDK5 is site-dependent, diminishing significantly in the presence of liver metastases.
    • CDK5 warrants further investigation as a potential therapeutic target or prognostic biomarker in specific mCRC patient subsets.